A new, ultrasensitive blood test checks for cancer cells remaining in the body after multiple myeloma treatment using blood samples instead of more invasive bone…
News
Enrollment is now complete for an early clinical study assessing the safety and tolerability of SENTI-202, Senti Biosciences’ cell therapy candidate for adults with…
PANCREATIC CANCER
FDA approves electrical field therapy Optune Pax for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved Novocure’s Optune Pax, a type of Tumor Treating Fields (TTFields) therapy, as a treatment for…
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning…
GYNECOLOGICAL CANCER
Ovarian cancer drug lira-cel extends survival ‘far longer’ than expected
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel,…
Anito-cel (anitocabtagene autoleucel), a cell therapy in clinical development as a potential treatment for myeloma, may be less likely to cause side effects than…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people…
PANCREATIC CANCER
FDA gives green light to first human trial testing cancer drug GTB-5550
A first-in-human clinical trial will launch in the coming months to test GTB-5550, an immune therapy from GT Biopharma that’s designed to treat various types…
A team of scientists at the University of Cincinnati Cancer Center is embarking on a series of tests to evaluate an experimental immune-modulating treatment strategy…
GYNECOLOGICAL CANCER
Prostate cancer tool may cut risk for women in radiation therapy
A long-lasting gel used to help protect the bowel during radiation therapy for prostate cancer may be successfully used in women with gynecological cancers…
Recent Posts
- Add-on mezigdomide slows cancer progression in hard-to-treat myeloma
- Even remission isn’t easy with multiple myeloma
- New AML trial targets patients unlikely to respond to standard therapy
- Ketogenic diet with chemo shows survival trend in pancreatic cancer
- Inovio, Akeso partner on Phase 2 trial of new immunotherapy for glioblastoma
